NCT00192270 - Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children | Biotech Hunter

Enrollment

498

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

January 31, 2001

Study Completion Date

January 31, 2001

Conditions

Healthy

Interventions

BIOLOGICAL

CAIV-T

Each dose of the vaccine was formulated to contain approximately 1 x 10\^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of \~3 x 10\^7 TCID50 per dose.

Trial Locations (3)

2610

University of Antwerp, Antwerp

3000

Dienst Jeugdgezondheidszorg, Leuven

90220

Oulu University Hospital, Oulu